Continuous Subcutaneous Glucose Monitoring in Critical Patients

E

European University

Status

Enrolling

Conditions

Hypoglycemia
Critical Care
Diabetes
Hyperglycemia
Critically Ill Patients

Study type

Observational

Funder types

Other

Identifiers

NCT06234787
MCGUCI1

Details and patient eligibility

About

This is a single-center, observational, descriptive, longitudinal, and prospective study This study aims to determine the cumulative incidence during admission and the incidence rate of potential hypoglycemic events (defined as subcutaneous glucose \<80 mg/dL detected by CGM) in patients admitted to the Intensive Care Unit (ICU) of HLA Moncloa Hospital over four years of follow-up. The study also aims to document the occurrences of hypoglycemic events, describe the characteristics of patients receiving CGM sensors, and outline the actions taken as a result of detecting potential hypoglycemic events

Full description

The disturbances in glycemic control, including type 1 and type 2 diabetes, are increasingly prevalent in the general population, with estimates suggesting that this trend will continue for at least the next 20 years. Critically ill patients are particularly predisposed to glycemic alterations due, among other factors, to stress, fasting, infections, and administered treatments. Hyperglycemia is detrimental to critically ill patients. Sustainedly elevated blood glucose levels lead to immunosuppression, hindering leukocyte function, reducing phagocytic capacity, and altering complement function. Furthermore, hyperglycemia enhances proinflammatory mechanisms and oxidative stress. Hemodynamic management is also affected, resulting in endothelial dysfunction and osmotic diuresis, promoting dehydration, electrolyte imbalances, and tissue hypoperfusion. For this reason, most current recommendations for glycemic control in critically ill patients advise insulin treatment when blood glucose levels exceed 180 mg/dL. However, the ideal glucose range for maintaining patients is still a subject of debate because, despite knowing that hyperglycemia is harmful, its treatment carries a high risk of hypoglycemia. Severe hypoglycemia (glucose <40 mg/dL) increases the risk of death by more than three times in critically ill patients. The incidence of hypoglycemia in critically ill patients varies widely depending on the type of patient and the protocol used for hyperglycemia control. Generally, it is estimated that between 3% and 20% of critically ill patients may experience severe hypoglycemia during their hospitalization. On the other hand, hypoglycemia can be easily prevented or treated in hospitalized patients through the infusion of glucose solutions if identified correctly. In recent years, the use of continuous subcutaneous glucose monitoring (CGM) sensors has revolutionized clinical practice for non-hospitalized diabetic patients. Subcutaneous glucose is directly related to capillary blood glucose and arterial blood glucose, so changes in blood glucose concentration will be transmitted to subcutaneous tissue within the next 5 to 10 minutes. CGM in critically ill patients has been shown to significantly reduce the incidence of hypoglycemia, mortality, and glycemic variability compared to standard practice. Given the current evidence, the Intensive Care Unit (ICU) at HLA Moncloa University Hospital has developed a guide for the use of CGM sensors in critically ill patients receiving insulin treatment, with the primary goal of reducing episodes of severe hypoglycemia in these patients. This guide has been in use since May 2023 (see ANNEX). The main utility of these sensors in critically ill patients is to detect individuals at risk of experiencing hypoglycemia, which the investigators may consider potential hypoglycemic events. However, to the best of our knowledge, there is currently no unified clinical practice regarding the use of these devices in critically ill patients, and it is not possible to find clinical practice guidelines or recommendations for the detection thresholds of potential hypoglycemic events or studies describing the characteristics of these events. Design: This is a single-center, observational, descriptive, longitudinal, and prospective study. Scope and Study Population: The study will be conducted on patients admitted to the ICU at HLA Moncloa Hospital over the course of four years. Procedures: All patients admitted to the Intensive Care Unit (ICU) who are potential candidates for inclusion in the study will be informed about it, and their informed consent will be requested. If patients agree to participate, the inclusion criteria will be ensured. Therefore, a continuous glucose monitoring sensor will be placed according to the detailed instructions in Annex 1. Patients will receive treatments according to the center's usual clinical practice and following the criteria of their responsible physician based on the patient's characteristics in each case. The device records glucose readings every 5 minutes. The information is automatically recorded on the reading device. If at any time the device detects a potential hypoglycemia, healthcare personnel will act according to the device placement guide (ANNEX 1), which details the procedure to follow. If confirmed, corrections will be made according to the criteria of the responsible physician. At the time of patient discharge or death, the principal investigator will review the patient medical history to create a pseudonymized database that includes the patient study variables, treatments, and duration of ICU stay, as well as the glucose records made by the continuous monitoring device. This information will be stored for 5 years on the hospital intranet server, along with other confidential information from the ICU at HLA Moncloa Hospital. Alarms: Alarms will be set up with the Freestyle Libre 2 sensor reader similarly for all patients. Low glucose alarm (subcutaneous glucose <80 mg/dL): After the alarm, capillary, arterial, or venous blood glucose will be checked, and actions will be taken according to the standard protocol of the ICU at HLA Moncloa Hospital. Definitions of hypoglycemia: Potential Hypoglycemia: Any continuous subcutaneous glucose measurement below 80 mg/dL confirmed by checking capillary, arterial, or venous blood glucose values up to 90 mg/dL (a margin of 10 mg/dL difference between subcutaneous glucose and blood glucose obtained will be accepted for hypoglycemia confirmation). Severe Hypoglycemia: Any glucose measurement below 40 mg/dL, whether in capillary, arterial, or venous blood. Moderate Hypoglycemia: Any glucose measurement between 40 and 54 mg/dL, whether in capillary, arterial, or venous blood. Mild Hypoglycemia: Any glucose measurement between 55 and 69 mg/dL, whether in capillary, arterial, or venous blood. False Hypoglycemia: Any continuous subcutaneous glucose measurement below 80 mg/dL is discarded by checking capillary, arterial, or venous blood glucose values above 90 mg/dL. Capillary, Arterial, and Venous Glucose: Critically ill patients routinely undergo glucose determinations several times throughout the day and in response to specific symptoms (dizziness, fatigue, weakness, headaches, confusion, speech disturbances, blurred vision, seizures, and coma). This includes capillary glucose measurements at the bedside, arterial blood gas analyses, or laboratory blood glucose tests on arterial or venous blood. The results of all glucose determinations performed on the patient will be systematically recorded. This way, the incidence and incidence rate of mild, moderate, and severe hypoglycemia occurring during hospitalization will be documented.

Enrollment

245 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • The study will be conducted in patients admitted to the ICU of HLA Moncloa Hospital over four years. Patients admitted to the ICU, undergoing insulin treatment, and having a CGM sensor.
  • Patients who sign the voluntary consent to participate in the study (Annex 2). If the participant is not in full physical or intellectual capacity to provide their signature on the informed consent, the responsible investigator will request such consent from their direct family member or the person legally designated to make decisions on their behalf regarding health matters. This measure is taken to ensure that the participant&#39;s rights are respected, and the integrity of the consent process is maintained, even in situations where their decision-making capacity may be compromised.

Exclusion criteria

  • Patients from whom information on CGM cannot be obtained for technical reasons.

Trial design

245 participants in 1 patient group

ICU Patients
Description:
Patients admitted to the Intensive Care Unit (ICU) at HLA Moncloa Hospital

Trial documents
2

Trial contacts and locations

1

Loading...

Central trial contact

Samuel G González, Doctor; Samuel G González, Doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems